Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.Global Wet Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035
Wet age-related macular degeneration is a progressive eye disease that is a leading cause of vision loss in individuals over the age of 50. It occurs when abnormal blood vessels grow under the retina, leaking fluid and causing damage to the macula, which is responsible for central vision. The condition severely affects the ability to read, recognize faces, and perform other tasks that require sharp vision. Wet age-related macular degeneration represents a major challenge for healthcare systems globally, as it significantly impacts the quality of life and imposes a high burden on individuals and economies.
The global wet age-related macular degeneration market is experiencing robust growth, driven by an aging population, increasing awareness about the condition, and advancements in treatment options. Key therapeutic approaches for wet age-related macular degeneration include anti-VEGF (vascular endothelial growth factor) therapies, photodynamic therapy, and laser surgeries, with the anti-VEGF drugs holding the largest market share due to their proven efficacy in halting or slowing disease progression. Furthermore, emerging treatments, including cell and gene therapy and stem cell therapy, are gaining attention as potential future solutions.
The most significant driver for the wet age-related macular degeneration market is the aging global population. As people live longer, the incidence of age-related eye conditions, including wet age-related macular degeneration, increases. Age-related macular degeneration is most common in individuals aged 65 and older, and as the world’s elderly population continues to grow, particularly in developed nations, the number of wet age-related macular degeneration cases rises. The UN projects that the number of people aged 80 and older will increase from 143 million in 2019 to 426 million by 2050, leading to a larger patient pool for wet age-related macular degeneration treatments.
Technologies such as optical coherence tomography (OCT) and fundus photography have greatly enhanced the ability to detect wet age-related macular degeneration at an early stage. Early diagnosis allows for timely intervention, helping to slow disease progression and improve patient outcomes. The adoption of advanced diagnostic tools in clinics and hospitals is driving market growth by enabling healthcare providers to identify patients who would benefit from anti-VEGF therapies or other treatments.
The wet age-related macular degeneration market is indeed growing due to increasing awareness, technological advances in treatments, and an aging global population. However, the combination of high treatment costs, side effects, limited access to care, and the ongoing challenge of offering curative treatments are significant factors restricting the market’s potential. Companies in the sector need to focus on reducing the cost of treatment, improving patient adherence, and advancing research to provide long-term and potentially curative therapies for Wet AMD. Addressing these challenges will be key to unlocking the market's full growth potential.
Some of the major players in the global wet age-related macular degeneration market, such as Regeneron Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, and Adverum Biotechnologies Inc., are continuously innovating to improve the effectiveness and comfort of wet age-related macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of wet age-related macular degeneration while enhancing their market positions globally.
The competitive landscape of the global wet age-related macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the wet age-related macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.
Market Segmentation:
Segmentation 1: by Treatment Type
In conclusion, the global wet age-related macular degeneration market is on track for continued growth, driven by the aging population, increasing awareness of wet age-related macular degeneration, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for wet age-related macular degeneration solutions rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving the quality of life for people living with incontinence.
This report will be delivered in 7-10 working days.Global Wet Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035
Wet age-related macular degeneration is a progressive eye disease that is a leading cause of vision loss in individuals over the age of 50. It occurs when abnormal blood vessels grow under the retina, leaking fluid and causing damage to the macula, which is responsible for central vision. The condition severely affects the ability to read, recognize faces, and perform other tasks that require sharp vision. Wet age-related macular degeneration represents a major challenge for healthcare systems globally, as it significantly impacts the quality of life and imposes a high burden on individuals and economies.
The global wet age-related macular degeneration market is experiencing robust growth, driven by an aging population, increasing awareness about the condition, and advancements in treatment options. Key therapeutic approaches for wet age-related macular degeneration include anti-VEGF (vascular endothelial growth factor) therapies, photodynamic therapy, and laser surgeries, with the anti-VEGF drugs holding the largest market share due to their proven efficacy in halting or slowing disease progression. Furthermore, emerging treatments, including cell and gene therapy and stem cell therapy, are gaining attention as potential future solutions.
The most significant driver for the wet age-related macular degeneration market is the aging global population. As people live longer, the incidence of age-related eye conditions, including wet age-related macular degeneration, increases. Age-related macular degeneration is most common in individuals aged 65 and older, and as the world’s elderly population continues to grow, particularly in developed nations, the number of wet age-related macular degeneration cases rises. The UN projects that the number of people aged 80 and older will increase from 143 million in 2019 to 426 million by 2050, leading to a larger patient pool for wet age-related macular degeneration treatments.
Technologies such as optical coherence tomography (OCT) and fundus photography have greatly enhanced the ability to detect wet age-related macular degeneration at an early stage. Early diagnosis allows for timely intervention, helping to slow disease progression and improve patient outcomes. The adoption of advanced diagnostic tools in clinics and hospitals is driving market growth by enabling healthcare providers to identify patients who would benefit from anti-VEGF therapies or other treatments.
The wet age-related macular degeneration market is indeed growing due to increasing awareness, technological advances in treatments, and an aging global population. However, the combination of high treatment costs, side effects, limited access to care, and the ongoing challenge of offering curative treatments are significant factors restricting the market’s potential. Companies in the sector need to focus on reducing the cost of treatment, improving patient adherence, and advancing research to provide long-term and potentially curative therapies for Wet AMD. Addressing these challenges will be key to unlocking the market's full growth potential.
Some of the major players in the global wet age-related macular degeneration market, such as Regeneron Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, and Adverum Biotechnologies Inc., are continuously innovating to improve the effectiveness and comfort of wet age-related macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of wet age-related macular degeneration while enhancing their market positions globally.
The competitive landscape of the global wet age-related macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the wet age-related macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.
Market Segmentation:
Segmentation 1: by Treatment Type
- Anti-VEGF Therapies
- Gene Therapy
- Others
- North America
- Europe
- Asia-Pacific
In conclusion, the global wet age-related macular degeneration market is on track for continued growth, driven by the aging population, increasing awareness of wet age-related macular degeneration, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for wet age-related macular degeneration solutions rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving the quality of life for people living with incontinence.
Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET: INDUSTRY OUTLOOK
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology of Wet Age-Related Macular Degeneration
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, $MILLION, 2023-2035
2.1 Anti-VEGF Therapies
2.2 Gene Therapy
2.3 Others
3. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, $MILLION, 2023-2035
3.1 North America
3.1.1 Key Findings
3.1.2 Market Dynamics
3.1.3 Market Sizing and Forecast
3.1.3.1 North America Wet Age-Related Macular Degeneration Market, by Country
3.1.3.1.1 U.S.
3.2 Europe
3.2.1 Key Findings
3.2.2 Market Dynamics
3.2.3 Market Sizing and Forecast
3.2.3.1 Europe Wet Age-Related Macular Degeneration Market, by Country
3.2.3.1.1 Germany
3.2.3.1.2 U.K.
3.2.3.1.3 France
3.2.3.1.4 Italy
3.2.3.1.5 Spain
3.3 Asia Pacific
3.3.1 Key Findings
3.3.2 Market Dynamics
3.3.3 Market Sizing and Forecast
3.3.3.1 Asia Pacific Wet Age-Related Macular Degeneration Market, by Country
3.3.3.1.1 Japan
4. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET: COMPETITIVE LANDSCAPE AND COMPANY PROFILES
4.1 Key Strategies and Developments by Company
4.1.1 Funding Activities
4.1.2 Mergers and Acquisitions
4.1.3 Regulatory Approvals
4.1.4 Partnerships, Collaborations and Business Expansions
4.2 Company Profiles
4.2.1 Regeneron Pharmaceuticals Inc
4.2.1.1 Overview
4.2.1.2 Top Products / Product Portfolio
4.2.1.3 Target Customers/End-Users
4.2.1.4 Key Personnel
4.2.1.5 Analyst View
4.2.2 Ophthotech Corporation
4.2.2.1 Overview
4.2.2.2 Top Products / Product Portfolio
4.2.2.3 Target Customers/End-Users
4.2.2.4 Key Personnel
4.2.2.5 Analyst View
4.2.3 Adverum Biotechnologies Inc
4.2.3.1 Overview
4.2.3.2 Top Products / Product Portfolio
4.2.3.3 Target Customers/End-Users
4.2.3.4 Key Personnel
4.2.3.5 Analyst View
4.2.4 Apellis Pharmeceuticals Inc
4.2.4.1 Overview
4.2.4.2 Top Products / Product Portfolio
4.2.4.3 Target Customers/End-Users
4.2.4.4 Key Personnel
4.2.4.5 Analyst View
4.2.5 Kubota Pharmaceutical Holdings Co. Ltd.
4.2.5.1 Overview
4.2.5.2 Top Products / Product Portfolio
4.2.5.3 Target Customers/End-Users
4.2.5.4 Key Personnel
4.2.5.5 Analyst View
4.2.6 Pfizer Inc.
4.2.6.1 Overview
4.2.6.2 Top Products / Product Portfolio
4.2.6.3 Target Customers/End-Users
4.2.6.4 Key Personnel
4.2.6.5 Analyst View
4.2.7 Novartis AG
4.2.7.1 Overview
4.2.7.2 Top Products / Product Portfolio
4.2.7.3 Target Customers/End-Users
4.2.7.4 Key Personnel
4.2.7.5 Analyst View
5. RESEARCH METHODOLOGY
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET: INDUSTRY OUTLOOK
1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology of Wet Age-Related Macular Degeneration
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Challenges
1.6.4 Market Opportunities
2. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, $MILLION, 2023-2035
2.1 Anti-VEGF Therapies
2.2 Gene Therapy
2.3 Others
3. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, $MILLION, 2023-2035
3.1 North America
3.1.1 Key Findings
3.1.2 Market Dynamics
3.1.3 Market Sizing and Forecast
3.1.3.1 North America Wet Age-Related Macular Degeneration Market, by Country
3.1.3.1.1 U.S.
3.2 Europe
3.2.1 Key Findings
3.2.2 Market Dynamics
3.2.3 Market Sizing and Forecast
3.2.3.1 Europe Wet Age-Related Macular Degeneration Market, by Country
3.2.3.1.1 Germany
3.2.3.1.2 U.K.
3.2.3.1.3 France
3.2.3.1.4 Italy
3.2.3.1.5 Spain
3.3 Asia Pacific
3.3.1 Key Findings
3.3.2 Market Dynamics
3.3.3 Market Sizing and Forecast
3.3.3.1 Asia Pacific Wet Age-Related Macular Degeneration Market, by Country
3.3.3.1.1 Japan
4. GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET: COMPETITIVE LANDSCAPE AND COMPANY PROFILES
4.1 Key Strategies and Developments by Company
4.1.1 Funding Activities
4.1.2 Mergers and Acquisitions
4.1.3 Regulatory Approvals
4.1.4 Partnerships, Collaborations and Business Expansions
4.2 Company Profiles
4.2.1 Regeneron Pharmaceuticals Inc
4.2.1.1 Overview
4.2.1.2 Top Products / Product Portfolio
4.2.1.3 Target Customers/End-Users
4.2.1.4 Key Personnel
4.2.1.5 Analyst View
4.2.2 Ophthotech Corporation
4.2.2.1 Overview
4.2.2.2 Top Products / Product Portfolio
4.2.2.3 Target Customers/End-Users
4.2.2.4 Key Personnel
4.2.2.5 Analyst View
4.2.3 Adverum Biotechnologies Inc
4.2.3.1 Overview
4.2.3.2 Top Products / Product Portfolio
4.2.3.3 Target Customers/End-Users
4.2.3.4 Key Personnel
4.2.3.5 Analyst View
4.2.4 Apellis Pharmeceuticals Inc
4.2.4.1 Overview
4.2.4.2 Top Products / Product Portfolio
4.2.4.3 Target Customers/End-Users
4.2.4.4 Key Personnel
4.2.4.5 Analyst View
4.2.5 Kubota Pharmaceutical Holdings Co. Ltd.
4.2.5.1 Overview
4.2.5.2 Top Products / Product Portfolio
4.2.5.3 Target Customers/End-Users
4.2.5.4 Key Personnel
4.2.5.5 Analyst View
4.2.6 Pfizer Inc.
4.2.6.1 Overview
4.2.6.2 Top Products / Product Portfolio
4.2.6.3 Target Customers/End-Users
4.2.6.4 Key Personnel
4.2.6.5 Analyst View
4.2.7 Novartis AG
4.2.7.1 Overview
4.2.7.2 Top Products / Product Portfolio
4.2.7.3 Target Customers/End-Users
4.2.7.4 Key Personnel
4.2.7.5 Analyst View
5. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Global Wet Age-Related Macular Degeneration Market, Dynamics Impact Analysis
Figure: Epidemiology of Wet Age-Related Macular Degeneration
Figure: Global Wet Age-Related Macular Degeneration Market Coverage
Figure: Global Wet Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Wet Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025
Figure: Global Wet Age-Related Macular Degeneration Market, Dynamics Impact Analysis
Figure: Epidemiology of Wet Age-Related Macular Degeneration
Figure: Global Wet Age-Related Macular Degeneration Market Coverage
Figure: Global Wet Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Wet Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025
LIST OF TABLES
Table: Global Wet Age-Related Macular Degeneration Market, Clinical Trial Analysis,
Table: Global Wet Age-Related Macular Degeneration Market Dynamics, Impact Analysis
Table: Global Wet Age-Related Macular Degeneration Market (by Treatmet Type), $Million, 2023-2035
Table: Global Wet Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035
Table: Global Wet Age-Related Macular Degeneration Market, Clinical Trial Analysis,
Table: Global Wet Age-Related Macular Degeneration Market Dynamics, Impact Analysis
Table: Global Wet Age-Related Macular Degeneration Market (by Treatmet Type), $Million, 2023-2035
Table: Global Wet Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035
